IK-175, an oral aryl hydrocarbon receptor inhibitor, alone and with nivolumab in patients with advanced solid tumors and urothelial carcinoma.

已完结 20 由何尘发布于 2026/9/19 23:30:12

DOI:10.1158/1078-0432.ccr-25-2013
作者：David H Aggen,Meredith McKean,Jean H Hoffman-Censits,Nehal J Lakhani,Omar Alhalabi,Elizabeth A Guancial,Babar Bashir,I Alex Bowman,Alan Tan,Trupti Lingaraj,Nerymar Ortiz-Otero,Wilmin Bartolini,Marissa
文献类型：期刊论文
补充材料：只需要正文

其它数据库

Abstract：PURPOSE Acquired resistance to anti-PD-1 therapy remains a major barrier to achieving durable responses in patients with solid tumors. The aryl hydrocarbon receptor (AHR) is a downstream me

应助信息

1天前

亮露

8567e6f2b48111f1b01034735aa3bc31.pdf 已采纳

1天前

Book学术机器人

2026/9/19 23:30:33 未找到该文献，机器人已退出，请等待人工下载

2026/9/19 23:30:12 Book学术AI机器人收到请求，开始寻找文献

2026/9/19 23:30:12 已向机器人发送请求

1天前

何尘发布求助

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:Sage Eculizumab as an adjunctive rescue treatment for life-threatening childhood onset of systemic lupus erythematosus.